on PREDILIFE (EPA:ALPRE)
Availability of the 2024 annual financial report by PREDILIFE
On June 6, 2025, PREDILIFE, a specialist in predicting disease risks using AI, released its 2024 annual financial report and filed it with the French Financial Markets Authority (Autorité des marchés financiers). This report, available online, had been delayed due to the spin-off of MammoRisk, a key milestone for the group.
Despite the certification of the consolidated accounts, the statutory auditor refused to certify the statutory accounts. The main reason was the inability to prove the transferability of loans included in the MammoRisk contribution agreement, which affected the accounting valuation.
In response, Predilife maintains that MammoRisk's valuation, supported by third-party studies, is in line with market standards. The company is preparing a fundraising round to support its continuity, scheduled to run until July 2025.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PREDILIFE news